Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
07:30am, Monday, 06'th Nov 2023
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wil
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
07:05am, Wednesday, 01'st Nov 2023
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian
Celcuity Inc. Announces $50 Million Private Placement
09:15am, Wednesday, 18'th Oct 2023
MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it h
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
04:43pm, Thursday, 21'st Sep 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
7 Short-Squeeze Stocks That Actually Might Make Sense
07:10pm, Wednesday, 06'th Sep 2023
Some of the most speculative ideas are the targeted short-squeeze stocks. To better understand what's going on, it's helpful to think of a timed chess match.
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
07:30am, Thursday, 03'rd Aug 2023
MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
08:00am, Wednesday, 24'th May 2023
MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian
Celcuity Inc. (CELC) Q1 2023 Earnings Call Transcript
10:47pm, Monday, 15'th May 2023
Celcuity Inc. (NASDAQ:CELC ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Conferen
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
05:30pm, Monday, 08'th May 2023
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication
Celcuity Inc. (CELC) Q4 2022 Earnings Call Transcript
08:04pm, Thursday, 23'rd Mar 2023
Celcuity Inc. (NASDAQ:CELC ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor G
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
08:00am, Thursday, 16'th Mar 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it w
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
07:35pm, Wednesday, 15'th Mar 2023
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publicati
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
07:30am, Tuesday, 22'nd Nov 2022
MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announce
Celcuity Inc. (CELC) Q3 2022 Earnings Call Transcript
05:16am, Sunday, 13'th Nov 2022
Celcuity Inc. (NASDAQ:CELC ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Go
